Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Birmingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Birmingham, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Janssen Research & Development, LLC17 Merck Sharp & Dohme LLC16 Eli Lilly and Company14 Bristol-Myers Squibb14
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Birmingham

478 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Birmingham, London, Glasgow, Cardiff, Manchester
2027-11-23
Not yet open
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics
Phase 1/2
20
Birmingham, Cambridge, London
2027-09
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
Market Research of a Slow Release Protein Substitute for the Dietary Management of PKU
NCT07802366Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn, Brain Disorder, Metabolic, Brain Diseases
metaX Institut fuer Diatetik GmbH
Not applicable
10
Birmingham
2026-10-15
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham
2026-09-29
Recruiting
HALEON
Not applicable
20
Birmingham
2026-09-28
Recruiting
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford
2026-09-17
Recruiting
Bristol-Myers Squibb
Phase 2
160
Birmingham, London, Guildford
2026-09-10
Recruiting
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-10
Recruiting
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
NCT07654855Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
AstraZeneca
Observational
320
Birmingham
2026-09-01
Recruiting
Salts Healthcare
Observational
108
Birmingham
2026-09
Not yet open
CooperVision International Limited (CVIL)
Not applicable
58
Birmingham
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ashton-under-Lyne, Basildon, Belfast, Birmingham, Brighton, Bristol, Cardiff, Clydebank
2026-08-24
Recruiting
CRISM Therapeutics LTD
Phase 2
147
Birmingham
2026-08-20
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
VectivBio AG
Phase 3
124
London, Aberdeen, Birmingham, Salford
2026-08
Recruiting
Amgen
Phase 3
950
Birmingham
2026-07-29
Recruiting
Boehringer Ingelheim
Phase 3
35
Birmingham, London
2026-07-21
Recruiting
Prilenia
Phase 3
400
Aberdeen, Birmingham, Cardiff, Liverpool, Newcastle upon Tyne
2026-07-01
Recruiting
ViiV Healthcare
Phase 3
564
Birmingham, Liverpool, London
2026-06-25
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
Takeda
Phase 3
300
Leicester, Boston, Oxford, Birmingham, London, Manchester
2026-05-21
Recruiting
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
By invitation
Recovery and Early Sleep Tracking Using the SuperPatch REM Patch
NCT07785960Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
SuperPatch Limited LLC
Not applicable
20
Birmingham
2026-05-15
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
30
Birmingham, London, Salford
2026-05-13
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
London, Birmingham, Leicester
2026-05-06
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
Hoffmann-La Roche
Phase 3
100
Birmingham, Cambridge, Sheffield
2026-04-15
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool
2026-03-16
Recruiting
Sanofi
Phase 2/3
526
Birmingham
2026-03-13
Recruiting
Avalyn Pharma Inc.
Phase 2
160
Exeter, Cottingham, Leicester, Birmingham
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, Liverpool, London, Manchester
2026-03-09
Active, closed
EasiVits Acceptability & Tolerance Study
NCT07619170Inborn Errors of Metabolism
NeoteriQ Ltd.
Not applicable
30
Birmingham
2026-03-07
Active, closed
Pfizer
Phase 3
1,078
Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston, Enfield
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Recruiting
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Sandbach, Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston
2025-12-19
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Birmingham
2025-12-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Birmingham, Glasgow, Liverpool, London, Manchester
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Birmingham, Cambridge, Cardiff, Newcastle
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
AstraZeneca
Phase 3
1,100
Birmingham, Glasgow, Greater London, Leeds, London, Manchester
2025-12-04
Recruiting
Eli Lilly and Company
Phase 3
7,140
Birmingham, Blackpool, Bromborough, Newcastle, Newquay, Poole, Rotherham, Torpoint
2025-12-01
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
75
Birmingham, Cambridge, Leicester, London, Manchester
2025-11-26
Recruiting
Debiopharm International SA
Phase 3
119
Birmingham, Leeds
2025-11-26
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Active, closed
Eli Lilly and Company
Phase 3
250
Birmingham, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford, Penzance
2025-11-17
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Birmingham, Cambridge, London
2025-11-10
Recruiting
AstraZeneca
Phase 2
435
Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool
2025-11-06
Recruiting
Takeda
Observational
10
Dorchester, Birmingham, London, Wrexham
2025-11-03
Recruiting
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Recruiting
Novo Nordisk A/S
Phase 1
30
Birmingham, London, Sheffield
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Birmingham, London, Metropolitan Borough of Wirral
2025-10-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Birmingham, Blackpool
2025-09-25
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff
2025-09-22
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston
2025-09-13
Recruiting
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belfast, Birmingham, Blackpool, Bodelwyddan, Bradford on Avon, Bristol, Bromborough, Enfield
2025-09-02
Recruiting
Ocus Innovation Ireland Limited
Phase 3
234
Belfast, Birmingham, London
2025-09-01
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 3
172
Birmingham, London, Manchester, Cottingham
2025-08-27
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Birmingham, Sheffield, Southampton
2025-08-21
Recruiting
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Active, closed
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive
DrugsBinimetinib·Encorafenib
Pierre Fabre Ltd
Observational
50
Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton
2025-07-31
Recruiting
Amgen
Phase 3
12,800
Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee
2025-07-25
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Birmingham, Blackburn, Bournemouth, Bradford, Bristol, Bromborough, Chichester, Cosham
2025-07-22
Recruiting
CSL Behring
Observational
200
Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds
2025-07-21
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Hoffmann-La Roche
Observational
700
Birmingham, Guildford, Leeds, Middlesbrough, Norfolk
2025-07-15
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Active, closed
Glycomine, Inc.
Phase 2/3
50
Birmingham
2025-07-09
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bellshill, Birmingham, Cardiff, London, Manchester
2025-07-02
Not yet open
Santersus AG
Not applicable
73
Birmingham, Edinburgh, Liverpool, London
2025-07-01
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-30
Recruiting
AbbVie
Phase 1/2
602
London, Birmingham, Cardiff
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Birmingham, High Wycombe, London, Middlesbrough, Southampton
2025-06-27
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Active, closed
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235Primary Hyperoxaluria Type 1 (PH1)
Arbor Biotechnologies
Phase 1/2
23
Birmingham, London
2025-06-16
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Recruiting
AstraZeneca
Phase 3
15,100
Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham
2025-06-04
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Birmingham, Glasgow, London
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Birmingham, Cardiff, London, Manchester
2025-05-21
Recruiting
GMP Powdered Substitutes in PKU and TYR
NCT06941532Phenylketonuria, Tyrosinemia
Nutricia UK Ltd
Not applicable
40
Birmingham
2025-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon
2025-05-13
Recruiting
Takeda
Phase 3
225
Aberdeen, Rhyl, Leicester, Lincoln, High Heaton, Sunderland, Birmingham, Cambridge
2025-05-06
Active, closed
Cartesian Therapeutics
Phase 3
128
Birmingham, Sheffield
2025-05-06
Recruiting
Mediar Therapeutics
Phase 2
164
Birmingham, Cambridge, Edinburgh, Oxford
2025-05-05
Active, closed
Pediatric Expansion Study of the Sentio System
NCT06976086Hearing Loss, Conductive, Hearing Loss, Mixed, Single Sided Deafness
Oticon Medical
Not applicable
50
Birmingham, London
2025-04-30
Recruiting
Hoffmann-La Roche
Phase 1
405
Birmingham, London
2025-04-30
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
London, Birmingham, Guildford, Manchester
2025-04-24
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Cottingham, Oxford, Birmingham, Cambridge, Leicester, London
2025-04-17
By invitation
Egoo Health Aps
Observational
20
Birmingham
2025-04-15
Recruiting
BeOne Medicines
Phase 3
250
Aberdeen, Birmingham, Bournemouth, London, Southampton
2025-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
Eli Lilly and Company
Phase 2
200
Birmingham, Blackpool, Bristol, Bromborough, Newcastle, Newquay, Nuneaton, Poole
2025-03-28
Recruiting
AstraZeneca
Phase 3
400
Belfast, Birmingham, Bradford, Bristol, Chorley, Leeds, Liverpool, Nottingham
2025-03-28
Recruiting
Eli Lilly and Company
Phase 3
700
Birmingham, East Sussex, Huddersfield, London, Manchester, Torquay
2025-03-27
Active, closed
Immutep S.A.S.
Phase 3
756
Birmingham, Guildford, Manchester
2025-03-21
Active, closed
Amgen
Phase 3
1,105
Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester
2025-03-17
Recruiting
Synergy Spine Solutions
Observational
50
Birmingham, London
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Active, closed
Amgen
Phase 3
3,853
Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull
2025-03-12
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Birmingham, London
2025-03-07
Recruiting
BeOne Medicines
Phase 3
300
Birmingham, Bournemouth, Glasgow, Headington, London, Metropolitan Borough of Wirral, Plymouth
2025-03-05
Active, closed
Eli Lilly and Company
Phase 3
643
Birmingham, Blackburn, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford
2025-03-05
Active, closed
AstraZeneca
Phase 2
57
Birmingham, London
2025-03-05
Recruiting
Incyte Corporation
Phase 3
600
Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford
2025-02-28
Recruiting
Daiichi Sankyo
Phase 3
726
Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester
2025-02-27
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2
200
Birmingham, London
2025-02-25
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Birmingham, Liverpool, London, Oxford
2025-02-10
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London
2025-02-06
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
London, Glasgow, Birmingham, Newcastle upon Tyne
2025-02-04
Recruiting
Physio-Assist
Not applicable
622
Belfast, Birmingham, Edinburgh, Manchester, Newcastle upon Tyne
2025-02-03
Recruiting
NovoCure GmbH
Phase 3
741
London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth
2025-02-01
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester
2025-01-28
Recruiting
BeOne Medicines
Phase 1/2
258
Birmingham, Leeds
2025-01-23
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Maidstone
2025-01-03
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Birmingham, London, Newcastle upon Tyne, Sheffield
2024-12-19
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Active, closed
AbbVie
Phase 2
185
London, Oxford, Birmingham, Dundee
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Birmingham, Cottingham, London, Manchester
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Hull, Leeds, London, Northwood
2024-12-12
Active, closed
AstraZeneca
Phase 2
24
Birmingham, Cambridge, London
2024-12-11
Active, closed
Vicore Pharma AB
Phase 2
378
Birmingham, Exeter, London, Manchester, Oxford
2024-12-09
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Bellshill, Birmingham, Cardiff, Hexham, London, Manchester
2024-12-03
Active, closed
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Recruiting
Salts Healthcare
Not applicable
27
Birmingham
2024-11-29
Active, closed
Daiichi Sankyo
Phase 3
700
Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay
2024-11-19
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Recruiting
Novartis Pharmaceuticals
Phase 1
106
Sutton, Birmingham, Glasgow
2024-11-11
Active, closed
Santhera Pharmaceuticals
Phase 4
80
Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle
2024-11-10
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
300
Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield
2024-10-18
Recruiting
argenx
Phase 3
69
Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro
2024-10-18
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Recruiting
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Active, closed
Incyte Corporation
Phase 2
130
Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2024-10-11
Active, closed
Gilead Sciences
Phase 3
609
Birmingham, Brighton, London
2024-10-09
Active, closed
Gilead Sciences
Phase 2
268
Birmingham, Brighton, Liverpool, London, Manchester
2024-10-07
Recruiting
AstraZeneca
Phase 3
744
Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough
2024-10-04
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Birmingham, London
2024-09-30
Recruiting
Takeda
Observational
500
Birmingham
2024-09-25
Active, closed
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London
2024-09-11
Recruiting
GlaxoSmithKline
Phase 3
440
Leicester, Birmingham, London
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Glasgow, Birmingham, Cambridge, London
2024-09-11
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel
2024-09-04
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Antrim, Basildon, Belfast, Birmingham, Blackburn, Brighton, Bristol, Bury St Edmunds
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London
2024-08-30
Active, closed
Gilead Sciences
Phase 3
640
Birmingham, Cambridge, Leeds, Leicester, London, Northwood
2024-08-28
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Recruiting
AstraZeneca
Phase 3
620
Birmingham, Dundee, Glasgow, Greater London, Leeds, London
2024-08-12
Active, closed
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
GlaxoSmithKline
Phase 3
10,212
Orpington, Bellshill, Metropolitan Borough of Wirral, Witney, Bradford on Avon, Belfast, Birmingham, Cardiff
2024-08-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Inverness, Swinton, Birmingham, London, Southampton
2024-07-31
Recruiting
Vitaccess Real MG Registry
NCT06064461Myasthenia Gravis
Vitaccess Ltd
Observational
600
London, Birmingham
2024-07-31
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Active, closed
Wave Life Sciences USA, Inc.
Phase 1/2
24
Birmingham, Cambridge, London
2024-07-19
Recruiting
Amgen
Phase 3
450
Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton
2024-07-17
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Birmingham, Glasgow, London
2024-06-25
Recruiting
Beam Therapeutics Inc.
Phase 1/2
192
Birmingham, London, Southampton
2024-06-19
Recruiting
H. Lundbeck A/S
Phase 2
18
Manchester, Birmingham
2024-06-19
Recruiting
Immunocore Ltd
Phase 3
680
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Active, closed
Amgen
Phase 1
120
Birmingham, London
2024-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Cambridge, Glasgow, Preston, London, Birmingham
2024-05-20
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
30
Birmingham
2024-05-14
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Recruiting
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
DrugVERVE-102
Verve Therapeutics, Inc.
Phase 1
85
Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham
2024-04-30
By invitation
Travere Therapeutics, Inc.
Phase 3
100
Birmingham, London, Salford
2024-04-30
Active, closed
Eli Lilly and Company
Phase 3
10,000
Aberdeen, Birmingham, Bromborough, Coventry, Glasgow, Hull, Ipswich, Lancashire
2024-04-30
Recruiting
CSL Behring
Phase 2/3
3,110
Birmingham, Bradford, Coventry, Derby, Dorchester, Liverpool, London, Londonderry
2024-04-27
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Cottingham, Birmingham, Glenfield, London, Londonderry, Oxford, Exeter, Wolverhampton
2024-04-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
43
Birmingham, Manchester, Sheffield
2024-04-02
Active, closed
Novo Nordisk A/S
Phase 3
673
Inverness, Chichester, Birmingham, Dundee, Peterborough
2024-04-01
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton
2024-04-01
Recruiting
Molecure S.A.
Phase 2
96
Birmingham, Cambridge, Edinburgh, London
2024-03-21
Active, closed
Cochlear
Not applicable
148
Birmingham, Bodelwyddan, London
2024-03-18
Recruiting
AstraZeneca
Phase 3
100
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
2024-03-14
Recruiting
PTC Therapeutics
Phase 3
56
Birmingham
2024-03-04
Active, closed
ULTRA LONG: BioFreedom Ultra
NCT05643430Coronary Artery Disease, High Bleeding Risk Patients
Biosensors Europe SA
Not applicable
86
Birmingham, Blackburn, Hull, Lincoln, Newport, Wigan
2024-02-27
Recruiting
Amicus Therapeutics
Observational
500
Birmingham, Cambridge, Cardiff, London, Manchester, Salford
2024-02-16
Active, closed
Biosensors Europe SA
Not applicable
85
Birmingham, Blackburn, Hull, Lincoln, Newport, Wigan
2024-02-09
Recruiting
Pfizer
Phase 3
492
Milton Keynes, Bodelwyddan, Bournemouth, Poole, Eastbourne, Worthing, Birmingham, London
2024-02-08
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Aberdeen, Birmingham, Boston, Bradford, Liverpool, London, Newport
2024-02-05
Active, closed
ReCode Therapeutics
Phase 2
128
Birmingham, Cambridge, Leeds, London, Nottingham, Southampton
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Birmingham, Dudley, Salford
2024-01-30
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Birmingham, Cardiff, Glasgow, Hexham, London, Manchester
2024-01-11
By invitation
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Birmingham, London, Salford
2023-12-28
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich
2023-12-20
Recruiting
Janssen-Cilag Ltd.
Observational
900
Birmingham, London, Wolverhampton
2023-12-18
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Active, closed
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Recruiting
Intellia Therapeutics
Phase 3
1,200
Birmingham, Cardiff, Glasgow, Hexham, Liverpool, London, Manchester
2023-12-13
Recruiting
AbbVie
Phase 3
110
Sheffield, London, Birmingham
2023-12-11
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Active, closed
Sanofi
Phase 2
197
Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow
2023-12-11
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Birmingham, Bristol, London, Sheffield
2023-12-08
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne
2023-12-01
Active, closed
ACADIA Pharmaceuticals Inc.
Phase 3
170
Birmingham, Glasgow, London
2023-11-27
Active, closed
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Active, closed
AbbVie
Phase 3
289
High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Birmingham
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Truro, Uxbridge, Birmingham, Aberdeen
2023-11-14
Recruiting
Takeda
Phase 3
80
London, Manchester, Nottingham, Birmingham
2023-11-13
Active, closed
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Recruiting
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Birmingham, Blackpool, Bury St Edmunds, Colchester, London, Truro
2023-10-24
Active, closed
Genentech, Inc.
Phase 2
260
Liverpool, Belfast, Birmingham, Cambridge, London
2023-10-18
Active, closed
Celgene
Phase 3
79
Birmingham, London
2023-10-16
By invitation
Biogen
Phase 3
306
London, Birmingham, Chapel Allerton
2023-10-03
Active, closed
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
By invitation
Denali Therapeutics Inc.
Phase 2/3
99
Birmingham, London, Manchester
2023-09-20
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Wakefield, Birmingham, Leeds, London, Portsmouth
2023-09-13
Active, closed
Bristol-Myers Squibb
Phase 3
774
Southampton, Wolverhampton, Birmingham, Cannock
2023-09-11
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Birmingham, Cambridge, Liverpool, London, Manchester, Preston
2023-09-07
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Birmingham, Glasgow, London
2023-08-31
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Active, closed
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
NCT05944432Diabetes Mellitus, Type 2
Abbott Diabetes Care
Not applicable
469
Ashton-under-Lyne, Bath, Birmingham, Cambridge, Darlington, Derby, Dundee, Harlow
2023-07-14
Active, closed
Novo Nordisk A/S
Phase 3
212
Birmingham, Bristol, Leeds, Liverpool, Southampton
2023-07-07
Recruiting
GEKO Venous Thromboembolism Prevention Study
NCT05476913Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Firstkind Ltd
Not applicable
1,200
Bury St Edmunds, Bath, Birmingham, Bournemouth, Bury, Cambridge, Canterbury, Chester
2023-07-06
Recruiting
Amgen
Phase 2
15
London, Birmingham
2023-07-03
Active, closed
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Birmingham, London, Salford
2023-06-27
Active, closed
Exact Sciences Corporation
Observational
416
Headington, Edinburgh, Birmingham, Worcester, Ipswich, Kidderminster, Redditch, Torquay
2023-06-20
Recruiting
ModernaTX, Inc.
Observational
60
Kirkcaldy, Manchester, City of London, Birmingham
2023-06-16
Recruiting
European Aortic Data Collection Project
NCT05896397Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection
Cook Research Incorporated
Observational
600
Birmingham, Bristol, London
2023-05-31
Recruiting
Takeda
Phase 3
240
London, Cardiff, Birmingham, Manchester
2023-05-16
Active, closed
Servier Affaires Médicales
Phase 3
299
Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne
2023-05-03
Active, closed
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Birmingham, Hull, London
2023-04-26
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Birmingham, Newcastle upon Tyne, Chelsea, Glasgow, London
2023-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 2
192
Birmingham, Leeds, London
2023-03-16
Recruiting
Vega Therapeutics, Inc
Phase 1/2
116
Birmingham, Southampton, London, Whitechapel
2023-03-16
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Blackpool, Birmingham, Chichester, Bradford, Bradford on Avon, Bristol, Chester, Coventry
2023-03-01
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Bristol, Winchester, London, Guildford, Birmingham, Plymouth
2023-02-28
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Active, closed
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
W.L.Gore & Associates
Observational
320
Birmingham, Walsall
2023-02-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
553
East Sussex, Crumpsall, London, Newcastle upon Tyne, Birmingham
2023-02-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Active, closed
Kite, A Gilead Company
Phase 3
300
Birmingham, Southampton
2023-02-10
Active, closed
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Birmingham, London, Nottingham
2023-02-03
Active, closed
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
Areteia Therapeutics
Phase 3
600
Bellshill, Birmingham, Bollington, Chorley, Enfield, Liverpool, London, Manchester
2023-01-30
Active, closed
Bristol-Myers Squibb
Phase 3
606
Plymouth, Cringleford, Glasgow, Birmingham, Leeds, Taunton
2023-01-10
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Birmingham, Leeds, London
2022-12-30
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Cottingham, Bellshill, Birmingham, Cardiff, Chesterfield, Chorley, Edinburgh, Hexham
2022-12-29
Active, closed
Ipsen
Phase 2
68
Aberdeen, Birmingham, Frimley, Glasgow, Hull, London
2022-12-29
Recruiting
H. Lundbeck A/S
Phase 1/2
42
Birmingham, Cambridge, London
2022-12-19
Recruiting
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Recruiting
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Amgen
Phase 3
7,297
Belfast, Birmingham, Blackpool, Bradford, Bristol, Chichester, Chippenham, Craigavon
2022-12-14
Active, closed
Hemab ApS
Phase 1/2
57
Birmingham, Leeds, London, Whitechapel
2022-12-13
Recruiting
Pfizer
Phase 3
100
Newcastle upon Tyne, Birmingham, London, Manchester
2022-12-09
Recruiting
Datum Dental LTD
Not applicable
65
Birmingham
2022-12-01
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool
2022-11-08
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Birmingham, Glasgow
2022-11-04
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
AstraZeneca
Observational
287
Aylesbury, Bath, Birmingham, Bournemouth, Cardiff, Cornwall, Dartford, Derby
2022-10-17
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Torquay, Huddersfield, Bedford, Birmingham, Bournemouth, Cardiff, Chelsea, Harrow
2022-10-04
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Birmingham, Devon, Glasgow, London, Sheffield
2022-09-23
Active, closed
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
Dentsply Sirona Implants and Consumables
Not applicable
139
Maidstone, Birmingham
2022-09-22
Active, closed
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
Vir Biotechnology, Inc.
Phase 2
95
Birmingham, London, Manchester
2022-09-17
Active, closed
Biogen
Phase 2/3
450
London, Manchester, Birmingham, Leeds
2022-09-13
Active, closed
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Active, closed
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Birmingham, Cambridge, London
2022-08-26
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Recruiting
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
Gilead Sciences
Phase 2/3
689
Birmingham, Brighton, London
2022-08-16
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
Denali Therapeutics Inc.
Phase 2/3
65
London, Birmingham, Salford
2022-07-21
Active, closed
GlaxoSmithKline
Phase 3
163
Birmingham, Cambridge, London
2022-07-14
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
154
Birmingham, Bristol, London
2022-07-13
Active, closed
Pfizer
Phase 2
108
Aberdeen, Birmingham
2022-07-11
Active, closed
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Active, closed
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Active, closed
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
Hoffmann-La Roche
Phase 2/3
97
Birmingham, Oxford
2022-06-02
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Birmingham, London
2022-05-30
Active, closed
Gilead Sciences
Phase 2
193
Birmingham, London
2022-05-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Recruiting
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Active, closed
Novo Nordisk A/S
Phase 3
153
Birmingham, Bristol, London
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Manchester, Northwood, Birmingham
2022-03-24
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Recruiting
ModernaTX, Inc.
Phase 1/2
56
Birmingham, Manchester
2022-03-08
Active, closed
Daiichi Sankyo
Phase 3
740
Birmingham, Nottingham
2022-03-04
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
Recruiting
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Penzance, Belfast, Birmingham, Blackpool, Cardiff, Durham, Enfield, Fowey
2022-02-07
By invitation
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Active, closed
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Quell Therapeutics Limited
Phase 1/2
33
Birmingham, Cambridge, London
2022-01-21
Recruiting
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Sheffield, Birmingham
2021-12-14
Recruiting
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
300
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Cardiff, Birmingham, London, Oxford, Plymouth
2021-11-30
Active, closed
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Recruiting
ModernaTX, Inc.
Phase 1/2
50
Manchester, Birmingham, London
2021-11-09
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Active, closed
Loxo Oncology, Inc.
Phase 3
282
Birmingham
2021-09-23
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Oxford
2021-09-09
Active, closed
Albireo, an Ipsen Company
Phase 3
62
Birmingham, London
2021-09-03
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Active, closed
Pfizer
Phase 3
118
London, Birmingham
2021-08-12
Active, closed
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
DrugTabelecleucel
Pierre Fabre Medicament
Phase 2
190
Birmingham, London
2021-07-14
Recruiting
Corcym S.r.l
Observational
2,150
Birmingham, Bristol, London
2021-06-29
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London
2021-06-24
Active, closed
Daiichi Sankyo
Phase 3
490
Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester
2021-05-21
Active, closed
Pfizer
Phase 3
599
Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London
2021-05-12
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
170
Chelsea, London, Manchester, Birmingham
2021-05-07
By invitation
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Recruiting
ModernaTX, Inc.
Phase 1/2
77
Birmingham, London, Manchester
2021-04-15
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Belfast, Birmingham, Coventry, Derby, Dundee, Exeter, Hull, Ipswich
2021-04-01
Active, closed
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Active, closed
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
London, Birmingham, Hampshire
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Birmingham, London, Manchester
2021-02-02
Recruiting
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Stryker Neurovascular
Observational
405
Birmingham, Edinburgh
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
AstraZeneca
Phase 3
358
Birmingham, Liverpool
2020-12-16
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
XVIVO Perfusion
Not applicable
230
Newcastle, Birmingham, Cambridge
2020-11-25
Active, closed
Medicago
Phase 2/3
30,918
Aberdeen, Birmingham, Bournemouth, Cardiff, Chelmsford, Chorley, Derby, Harrow
2020-11-19
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Birmingham, London, Salford
2020-10-01
Active, closed
AAV Gene Therapy Study for Subjects with PKU
NCT04480567Phenylketonuria (PKU)
BioMarin Pharmaceutical
Phase 1/2
100
Birmingham
2020-09-24
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Birmingham, London, Sandwich
2020-08-20
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
Incyte Corporation
Phase 2
112
Birmingham
2020-08-03
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Genentech, Inc.
Phase 1
498
Birmingham, Cardiff, London, Manchester
2020-07-29
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Leeds, Birmingham, London
2020-07-13
Active, closed
Eli Lilly and Company
Phase 3
1,736
Motherwell, London, Guildford, Birmingham
2020-06-19
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Liverpool, Birmingham, Cardiff, Glasgow, London
2020-03-12
Active, closed
BeOne Medicines
Phase 3
955
Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds
2020-01-16
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
DrugLAM561
Laminar Pharmaceuticals
Phase 2/3
144
Newcastle, Birmingham, Cambridge, London
2019-12-01
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Bellshill, London, Londonderry, Hexham, Birmingham, Cardiff, Manchester
2019-11-26
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
DrugTobemstomig
Hoffmann-La Roche
Phase 1/2
170
Birmingham, Manchester
2019-11-11
Recruiting
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Active, closed
Novo Nordisk A/S
Phase 3
134
Birmingham, London, Manchester, Nottingham, Sheffield
2019-10-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Active, closed
RECORDATI GROUP
Observational
125
Newcastle upon Tyne, Birmingham, Southampton
2019-09-30
Active, closed
BeOne Medicines
Phase 3
510
Abergavenny, Birmingham, Dudley, Sutton
2019-08-20
Active, closed
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
DrugDcr-Phxc
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 3
75
Hampstead, Birmingham
2019-07-09
Active, closed
Ceramisys Ltd
Observational
220
Doncaster, Birmingham, North Shields, Salford, Stoke-on-Trent, Taunton
2019-06-13
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Birmingham, Cambridge, Chorley, Hardwick, Liverpool, London, Manchester, Newcastle upon Tyne
2019-03-28
Active, closed
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
Advanced Accelerator Applications
Observational
1,014
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield
2018-11-28
Active, closed
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
NCT03636438Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc
Observational
11
Birmingham
2018-08-30
Active, closed
Gilead Sciences
Phase 2
502
Birmingham, London, Northwood, Surrey
2018-08-13
Active, closed
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Recruiting
Octapharma
Observational
200
Headington, Birmingham, London, Newcastle upon Tyne
2018-02-13
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
DrugTabelecleucel
Pierre Fabre Medicament
Phase 3
115
Birmingham, London
2017-12-29
Active, closed
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness
2017-09-12
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Active, closed
Medtronic
Observational
1,092
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2017-08-21
Active, closed
Pfizer
Phase 3
296
Ipswich, Birmingham, Manchester
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Active, closed
ViiV Healthcare
Phase 3
631
Birmingham, Coventry, Leeds Yorkshire, London
2016-10-27
Active, closed
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Celgene
Phase 1/2
130
Birmingham, Headington, London, Sutton (Surrey)
2016-06-03
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Birmingham, London
2015-11-02
Active, closed
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral
2014-11-26
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Active, closed
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Cambridge, London, Manchester, Salford, Birmingham
2013-05-30
Active, closed
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity
Zimmer Biomet
Observational
255
Birmingham
2012-03
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Barnstaple, Birmingham, Blackpool, Bristol, Chelmsford, Glasgow, Harrow, Leeds
2012-01
Active, closed
AstraZeneca
Phase 2
162
Birmingham, Coventry, Edinburgh
2010-02-04
Recruiting
Esteve Pharmaceuticals, S.A.
Observational
500
Belfast, Birmingham, Leeds, London, Manchester
2008-12-09
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne
2004-09-15
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Cambridge, Birmingham, London, Salford, Belfast, Manchester
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Cambridge, Birmingham, London, Salford, Manchester
1991-04-01
Recruiting
Medtronic
Observational
20,000
Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester
1983-01
Rows per page Showing 1–478 of 478
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/birmingham

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 478 of those studies with a site in Birmingham.

How many clinical trials are recruiting in Birmingham?

224 of the 478 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 7 have not yet opened recruitment, 232 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Birmingham), 478 studies
PhaseStudiesRecruitingShare
Phase 325610653.6%
Phase 2753515.7%
Observational523210.9%
Phase 1/235237.3%
Phase 2/324135%
Not applicable2384.8%
Phase 11072.1%
Phase 4300.6%

Most active sponsors

Lead sponsors with the most studies (Birmingham)
Lead sponsorStudiesRecruiting
AstraZeneca3115
Janssen Research & Development, LLC179
Merck Sharp & Dohme LLC1612
Bristol-Myers Squibb148
Eli Lilly and Company147
AbbVie133
Novo Nordisk A/S135
Pfizer123
Amgen117
Hoffmann-La Roche104
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.